Skip to main content
PepStack
Blutwerte · Marker

Aldosteron

Aldosterone · Mineralocorticoid

Hormone — StressachseZeitabhängig
Einheit:
nmol/L
Abbreviation
Aldo

Aldosterone quantifies the level of the mineralocorticoid hormone involved in sodium and potassium regulation.

Reference Ranges

Reference
0.14–0.55nmol/L
0.14
0.55
LowNormalHigh
Reference
Unit · nmol/L

Levels can vary with posture, time of day, and sodium intake.

Overview

Übersicht

Aldosterone (Aldo), a mineralocorticoid hormone produced by the adrenal glands, plays a crucial role in regulating sodium and potassium balance, as well as blood pressure. It acts primarily on the distal nephron of the kidney to promote sodium reabsorption and potassium excretion, thereby influencing fluid balance and systemic vascular resistance. Researchers have observed that aldosterone is a key component of the renin-angiotensin-aldosterone system (RAAS), which is activated in response to low blood volume or pressure. Clinically, aldosterone levels are significant in diagnosing and managing conditions such as primary aldosteronism, heart failure, and chronic kidney disease. Elevated aldosterone is often associated with hypertension and cardiovascular risk, while low levels may indicate adrenal insufficiency, such as Addison's disease. In the context of athletic performance and biohacking, aldosterone's role in fluid and electrolyte balance can impact endurance and recovery. Biohackers may monitor aldosterone to optimize hydration and electrolyte status, potentially enhancing performance and longevity. However, researchers found that aldosterone levels can be influenced by various factors, including time of day, posture, and dietary sodium intake. Testing should ideally be conducted in the morning and under standardized conditions to ensure accuracy. Additionally, certain medications, stress, and renal function can interfere with aldosterone measurements, necessitating careful interpretation of results.

Klinische Bedeutung

Elevated aldosterone levels indicate conditions like primary aldosteronism or secondary hyperaldosteronism, often associated with hypertension. Reduced levels suggest adrenal insufficiency, such as Addison's disease.

Dynamics

Trend Interpretation

Rising Values

Progressively rising aldosterone suggests worsening hypertension or heart failure; re-test in 4 weeks if outside optimal range.

Falling Values

Falling aldosterone may indicate adrenal insufficiency or effective treatment of hyperaldosteronism.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Primary aldosteronism
  • Chronic kidney disease
  • Congestive heart failure
  • Renal artery stenosis
  • Excessive sodium intake
Cause

Low Levels

  • Addison's disease
  • Congenital adrenal hyperplasia
  • Hypopituitarism
  • Chronic stress
  • Low sodium intake
Protocol

How to Optimize

Lever

Lifestyle

  • Regular physical activity
  • Stress management techniques
  • Adequate hydration
  • Sleep optimization
Lever

Nutrition

  • Balanced sodium intake
  • Potassium-rich foods
  • Adequate water consumption

Note:

Consult a healthcare provider before making significant dietary or lifestyle changes, especially if on medication.

Testing Guidelines

✓Fasting Not Required
🕐Time-Sensitive

Aldosterone levels peak in the morning; testing should be consistent in timing.

Testing Frequency

Annually for individuals with hypertension or adrenal disorders.

Interfering Factors

  • Posture changes
  • Dietary sodium intake
  • Medications like diuretics

Related Peptides & Hormones

Cortisol

Correlated with

hormone

Open Research Questions

Current research suggests that the optimal aldosterone reference ranges and targets for specific populations, such as those with primary aldosteronism or cardio-kidney diseases, remain debated. Researchers have not yet established the full clinical implications of compensatory neurohormonal activation in patients on mineralocorticoid receptor antagonists. Additionally, unanswered clinical questions include the long-term effects of emerging aldosterone synthase inhibitors and the best strategies for monitoring disease progression in patients with primary aldosteronism.

35 Research Publications

846

Total Citations

6

Human/RCT

3.2

Avg. Influence

2024

Latest

Sort
Filter
#01

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Meta-AnalysisInfluence12.0
180
Researchers conducted a meta-analysis on the effects of sodium-glucose cotransporter 2 inhibitors in people with type 2 diabetes. They found that these inhibitors reduce the risk of serious hyperkalemia without increasing the risk of hypokalemia.
View on PubMed
#02

Independent regulation of renin-angiotensin-aldosterone system in the kidney.

ReviewInfluence4.0
112
View on PubMed
#03

BNP as a Major Player in the Heart-Kidney Connection.

Review
88
View on PubMed
#04

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.

HumanInfluence8.0
68
This study evaluated the safety and pharmacokinetics of baxdrostat, an aldosterone synthase inhibitor, in healthy volunteers. Researchers observed a dose-dependent reduction in plasma aldosterone levels, indicating its potential for managing conditions associated with elevated aldosterone.
View on PubMed
#05

Canine hypoadrenocorticism: pathogenesis, diagnosis, and treatment.

ReviewInfluence4.0
59
This study focused on hypoadrenocorticism in dogs, detailing its pathogenesis and diagnosis. Researchers found that immune-mediated destruction of adrenal glands leads to decreased hormone production, and diagnosis often requires specific hormone level testing.
View on PubMed
#06

Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.

ReviewInfluence1.0
56
Researchers explored the clinical significance of hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors, noting it as a common adverse effect. The study emphasized the need for effective management strategies to mitigate hyperkalemia while allowing continued use of these beneficial medications.
View on PubMed
#07

Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.

ReviewInfluence2.0
41
This review explored the role of aldosterone in cardio-kidney diseases. Researchers observed that excess aldosterone contributes to inflammation and dysfunction in the heart and kidneys, and that mineralocorticoid receptor antagonists may mitigate these effects.
View on PubMed
#08

Renal Na-handling defect associated with PER1-dependent nondipping hypertension in male mice.

AnimalInfluence1.0
39
This study explored the role of the circadian clock gene PER1 in regulating blood pressure and sodium handling in mice. Researchers found that PER1 deficiency led to nondipping hypertension and inappropriate regulation of sodium transport genes, suggesting a link between circadian rhythms and blood pressure control.
View on PubMed
#09

A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.

ReviewInfluence1.0
37
This review analyzed the effects of finerenone, a new mineralocorticoid receptor antagonist. Researchers observed that it shows promise in treating cardiovascular and renal diseases, particularly in patients with type 2 diabetes and chronic kidney disease.
View on PubMed
#10

Determination of aldosterone in human serum by isotope dilution gas chromatography/mass spectrometry using a new heptafluorobutyryl derivative.

In Vitro
32
Researchers developed a new heptafluorobutyryl derivative of aldosterone for gas chromatography/mass spectrometry analysis. This method showed high sensitivity and stability, allowing for accurate measurement of aldosterone levels in serum. The findings were validated through agreement between results from two laboratories.
View on PubMed

Clinical Trials (1)

1

Total Trials

20

Total Enrolled

Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism

NCT06478875Phase 2NOT_YET_RECRUITING
Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

20

Started

2024

Primary outcome

relevant biomarkers strongly associated with primary lateralized hyperaldosteronism

Primary Aldosteronism

Publication Trend

Research publications about Aldosteron over time

10total
1
'14
2
'18
1
'19
1
'21
2
'22
2
'25
1
'26

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer